Published:
Bristol Myers Squibb needs more time to run a late-stage study for one of its most promising drugs, delaying a readout that’s key to the company’s future.
Yet the stock
BMY was up about 6% on Wednesday after the drug giant announced the delay. In its statement, the company said it now expects to share the data from the Phase 3 trial sometime next year. Bristol Myers had expected the readout for Cobenfy in Alzheimer’s disease psychosis to land before the end of 2025.
